S&P 500   5,092.84 (+0.08%)
DOW   39,245.83 (+0.29%)
QQQ   437.45 (+0.15%)
AAPL   181.98 (-0.30%)
MSFT   410.94 (+0.15%)
META   482.08 (-0.40%)
GOOGL   140.78 (-2.21%)
AMZN   175.25 (+0.15%)
TSLA   194.91 (+1.53%)
NVDA   802.47 (+1.81%)
NIO   5.66 (+4.81%)
AMD   178.11 (+0.90%)
BABA   76.20 (+0.32%)
T   16.79 (-0.06%)
F   12.14 (+0.00%)
MU   90.28 (+4.98%)
CGC   3.42 (+1.79%)
GE   154.13 (+0.52%)
DIS   107.90 (+0.15%)
AMC   4.48 (+0.90%)
PFE   27.46 (-1.08%)
PYPL   59.06 (-0.17%)
XOM   103.57 (-0.26%)
S&P 500   5,092.84 (+0.08%)
DOW   39,245.83 (+0.29%)
QQQ   437.45 (+0.15%)
AAPL   181.98 (-0.30%)
MSFT   410.94 (+0.15%)
META   482.08 (-0.40%)
GOOGL   140.78 (-2.21%)
AMZN   175.25 (+0.15%)
TSLA   194.91 (+1.53%)
NVDA   802.47 (+1.81%)
NIO   5.66 (+4.81%)
AMD   178.11 (+0.90%)
BABA   76.20 (+0.32%)
T   16.79 (-0.06%)
F   12.14 (+0.00%)
MU   90.28 (+4.98%)
CGC   3.42 (+1.79%)
GE   154.13 (+0.52%)
DIS   107.90 (+0.15%)
AMC   4.48 (+0.90%)
PFE   27.46 (-1.08%)
PYPL   59.06 (-0.17%)
XOM   103.57 (-0.26%)
S&P 500   5,092.84 (+0.08%)
DOW   39,245.83 (+0.29%)
QQQ   437.45 (+0.15%)
AAPL   181.98 (-0.30%)
MSFT   410.94 (+0.15%)
META   482.08 (-0.40%)
GOOGL   140.78 (-2.21%)
AMZN   175.25 (+0.15%)
TSLA   194.91 (+1.53%)
NVDA   802.47 (+1.81%)
NIO   5.66 (+4.81%)
AMD   178.11 (+0.90%)
BABA   76.20 (+0.32%)
T   16.79 (-0.06%)
F   12.14 (+0.00%)
MU   90.28 (+4.98%)
CGC   3.42 (+1.79%)
GE   154.13 (+0.52%)
DIS   107.90 (+0.15%)
AMC   4.48 (+0.90%)
PFE   27.46 (-1.08%)
PYPL   59.06 (-0.17%)
XOM   103.57 (-0.26%)
S&P 500   5,092.84 (+0.08%)
DOW   39,245.83 (+0.29%)
QQQ   437.45 (+0.15%)
AAPL   181.98 (-0.30%)
MSFT   410.94 (+0.15%)
META   482.08 (-0.40%)
GOOGL   140.78 (-2.21%)
AMZN   175.25 (+0.15%)
TSLA   194.91 (+1.53%)
NVDA   802.47 (+1.81%)
NIO   5.66 (+4.81%)
AMD   178.11 (+0.90%)
BABA   76.20 (+0.32%)
T   16.79 (-0.06%)
F   12.14 (+0.00%)
MU   90.28 (+4.98%)
CGC   3.42 (+1.79%)
GE   154.13 (+0.52%)
DIS   107.90 (+0.15%)
AMC   4.48 (+0.90%)
PFE   27.46 (-1.08%)
PYPL   59.06 (-0.17%)
XOM   103.57 (-0.26%)
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

$575.50
-0.79 (-0.14%)
(As of 09:33 AM ET)
Today's Range
$575.50
$576.49
50-Day Range
$515.08
$576.29
52-Week Range
$372.50
$579.68
Volume
5,587 shs
Average Volume
446,962 shs
Market Capitalization
$47.82 billion
P/E Ratio
57.15
Dividend Yield
N/A
Price Target
$591.50

IDEXX Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
2.6% Upside
$591.50 Price Target
Short Interest
Healthy
2.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
0.92mentions of IDEXX Laboratories in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$34.60 M Sold Last Quarter
Proj. Earnings Growth
14.73%
From $11.13 to $12.77 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

116th out of 935 stocks

Diagnostic Substances Industry

3rd out of 13 stocks


IDXX stock logo

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock Price History

IDXX Stock News Headlines

Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
IDXX Jun 2024 640.000 call
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
IDXX Feb 2024 550.000 call
IDEXX Laboratories Inc Insider Sells Shares
Q4 2023 IDEXX Laboratories Inc Earnings Call
IDEXX Laboratories Shares Rise On Upbeat Q4 Results
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
2/26/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,780
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$591.50
High Stock Price Target
$655.00
Low Stock Price Target
$460.00
Potential Upside/Downside
+2.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$845.04 million
Pretax Margin
28.99%

Debt

Sales & Book Value

Annual Sales
$3.66 billion
Cash Flow
$10.91 per share
Book Value
$17.86 per share

Miscellaneous

Free Float
81,347,000
Market Cap
$47.89 billion
Optionable
Optionable
Beta
1.25

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of IDEXX Laboratories was last updated on Tuesday, February 20, 2024 at 10:35 PM.

Pros

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • Recent increase in stock value, showing potential for growth.
  • Strong presence in companion animal veterinary market, providing stable revenue streams.
  • Diversified product portfolio catering to various markets like livestock, poultry, and water testing.
  • Ongoing development of innovative diagnostic products, ensuring competitiveness in the industry.
  • Consistent financial performance and revenue growth over the past quarters.

Cons

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • Dependency on the veterinary and livestock markets, susceptible to fluctuations in these industries.
  • Competitive landscape with other diagnostic companies, potentially impacting market share.
  • Regulatory challenges in the healthcare equipment industry affecting product development and sales.
  • Market volatility and economic uncertainties impacting investor confidence.
  • Potential impact of global events like pandemics on demand for diagnostic products.














IDXX Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price target for 2024?

9 equities research analysts have issued twelve-month target prices for IDEXX Laboratories' shares. Their IDXX share price targets range from $460.00 to $655.00. On average, they anticipate the company's share price to reach $591.50 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2024?

IDEXX Laboratories' stock was trading at $555.05 on January 1st, 2024. Since then, IDXX shares have increased by 3.8% and is now trading at $576.29.
View the best growth stocks for 2024 here
.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 1,850,000 shares, an increase of 6.3% from the January 15th total of 1,740,000 shares. Based on an average daily volume of 492,400 shares, the days-to-cover ratio is presently 3.8 days. Currently, 2.3% of the company's stock are short sold.
View IDEXX Laboratories' Short Interest
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our IDXX earnings forecast
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings data on Monday, February, 5th. The company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a trailing twelve-month return on equity of 71.66%. The firm's quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.05 earnings per share.
Read the conference call transcript
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY 2024 earnings guidance on Monday, February, 5th. The company provided earnings per share (EPS) guidance of 10.840-11.330 for the period, compared to the consensus earnings per share estimate of 11.000. The company issued revenue guidance of $3.9 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.08%), Franklin Resources Inc. (1.69%), Brown Advisory Inc. (1.39%), Capital World Investors (1.23%), Norges Bank (1.11%) and Northern Trust Corp (1.04%). Insiders that own company stock include Brian P Mckeon, Daniel M Junius, George Fennell, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDXX) was last updated on 2/26/2024 by MarketBeat.com Staff